Skip to content

Trial Summary

 The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.



ACTRN/NCT /ethics:


Scientific title:

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Sponsor / Cooperative group:

Panbela Therapeutics, Inc.

Trial & Patient Characteristics

Cancer TypePancreas
Trial TypeTreatment
PhasePhase II & Phase III
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-08-08
Anticipated End Date2024-05-31

Participating Hospitals

HospitalIcon Cancer Centre - Tennyson and Windsor Garden
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorCarolyn Bampton
Recruitment StatusRecruiting